Additionally, an increasing number of studies are showing positive cardiovascular outcomes in blood pressure, dyslipidemia, and biomarkers in patients treated with GLP-1RAs [59,60,61,62,63,64]
He added that the gastrointestinal risks arent trivial. A 2025 study in BMJ Open Gastroenterology discovered that people taking Wegovy, Ozempic or Rybelsus had a higher risk of developing gastroparesis
Effects of L-carnitine on exercise tolerance in chronic stable angina: a multicenter, double-blind, randomized, placebo-controlled, crossover study
Wegovy, the weight loss medication made by Novo Nordisk, is listed at $1,349 in the U.S
32 Vining CC, Hsu PJ, Miller A, et al